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ABSTRACT
THE REGULATION OF ATG9A-MEDIATED AGGREPHAGY BY AN ULK1INDEPENDENT ATG13-ATG101 COMPLEX
Joshua Youngs
Department of Chemistry and Biochemistry
Bachelor of Science

Aggrephagy, a type of autophagy, is an essential cellular process by which protein
aggregates are collected and broken down in the lysosome. Protein aggregates are
implicated in several diseases including Alzheimer’s disease, diabetes, and cancer.
Here, we investigate the ATG13-ATG101 protein complex, a sub-complex of the
canonical ULK1 complex whose regulatory role in aggrephagy is not completely
understood. We also develop a protein fragment complementation (PFC) assay
using the biotin ligase TurboID to study the functions of the ATG13-ATG101
complex with increased specificity. We demonstrate that ATG13 is required for
optimal degradation of p62-ubiquitin condensates. We also show that a lack of
ATG13 expression causes a deficiency in autophagic flux as indicated by the
accumulation of ATG9A positive p62-ubiquitin condensates. This function is
mediated by ATG13 and requires ATG101, suggesting that this is a phenomenon
of ATG13 and ATG101 in complex. Lastly, we use the split TurboID PFC assay to
observe the interaction between the whole ATG13-ATG101 complex and ATG9A
using an ULK1 non-binding mutant of ATG13, validating the existence of an
ATG13-ATG101 complex with functions independent of the ULK1 complex.
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INTRODUCTION
The aggregation of proteins is, to one extent, essential, and to another
extent, greatly deleterious to the viability of the cell. In recent years, it has been
shown that the localized concentration of proteins into phase separated
condensates through a process termed Liquid-Liquid Phase Separation (LLPS) is
of functional value to the cell.1 Such condensates as the nucleolus, P bodies, and
stress granules act to localize and transiently compartmentalize functions
necessary to the cell.2, 3 Aberrant protein aggregation and condensation is harmful
to the cell and is a primary cause of many diseases including Alzheimer’s disease,
diabetes, sickle cell anemia, and, as is being increasingly discovered, certain types
of cancer.1, 4
One method by which aberrant protein aggregates are degraded is
selective autophagy or aggrephagy, a specific type of the cellular recycling
pathway autophagy. This role of aggrephagy implicates this complex pathway in
the menagerie of protein aggregate diseases, principle of which in this
investigation is cancer. The relationship of aggrephagy with cancer is nuanced,
neither being wholly supportive of nor wholly deleterious to oncogenesis or tumor
proliferation. Understanding the mechanism of aggrephagy will afford researchers
and clinicians a better knowledge of how to target and treat cancers in which
aggrephagy is implicated.
Aggrephagy begins with the ubiquitination of protein aggregates, closely
followed by binding of the adaptor protein p62 to those ubiquitin chains and the
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formation of p62 condensates through LLPS.5 Autophagy machinery is then
recruited to this site of p62 condensation to form and elongate a double-layered
lipid structure known as the autophagosome. After the autophagosome has fully
encapsulated the original debris, it is trafficked to the lysosome for degradation.
Autophagy has traditionally been studied in the context of metabolic
stress, and more specifically in the context of energy deprivation, which can arise
from both hypoxia and nutrient deprivation. As ADP and AMP levels rise in the
cytosol, AMP-activated protein kinase (AMPK) is activated by phosphorylation.6
Activated AMPK performs two compound functions in the activation of
autophagy. First, AMPK inhibits the protein complex mTORC1.
mTORC1inhibits autophagy by phosphorylating ULK1/2. Second, AMPK
directly phosphorylates ULK1/2, activating it.7
Activated ULK1/2 phosphorylates several substrates. These include all
three members of the ULK1 initiatory complex: FIP200, ATG13, and ATG101. In
addition to ULK1 complex members, ULK1 phosphorylates BECLIN-1, VPS34,
ATG14L, and ATG4B, increasing lipidation and integration if LC3-II into the
elongating autophagosome.8, 9
LC3 is a protein responsible for anchoring the autophagosome to cargo by
binding to adaptor proteins such as p62. LC3 must go through two major changes
to be incorporated into the membrane of the autophagosome. First, ATG4 cleaves
the N-terminus of LC3, generating LC3-I. Next, in a manner similar to the
conjugation of ubiquitin to proteins, LC3-I is conjugated to PI3P by several
proteins including ATG7, ATG3, and the heterotrimer ATG12/ATG16L/ATG5.
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An additional substrate of ULK1 is ATG9A, which is a transmembrane
vesicle protein implicated in the elongation of the autophagosome and regulation
of autophagy.10 Guardia et al. found that ATG9A exists primarily as a trimer, the
protomers of which exist in a dynamic confirmation.11 Matoba et al. discovered
that ATG9A has lipid scramblase activity which is mediated by a domaindependent confirmational change in the ATG9A trimer. Additionally, they
discovered that ATG9A positive liposomes contain phosphorylated lipids on both
leaflets compared to ATG9A-negative liposomes, which only contain
phospholipids on the outer leaflet.12 Because PI3P is required for LC3 lipidation
and cargo anchoring, ATG9A may play an essential role in providing PI3P to the
inner leaflet of the autophagosome during elongation. These data strengthen the
assertion that ATG9A is an essential regulator of autophagy.
The relationship between ATG9A and the ULK1 complex is poorly
understood. Early studies by Zhou et al. show that ULK1 directly phosphorylates
ATG9A at Serine 14. This phosphorylation event is required for ULK1-mediated
redistribution of ATG9A to endosomes under conditions of metabolic stress.10
Thus, under conditions of metabolic stress, direct interaction between ULK1 and
ATG9A is required for the initiation of autophagy. These data suggest that ULK1
has an important role in initiating ATG9A-mediated autophagy; however, little is
known about the function of the other members of the ULK1 complex.
FIP200, the largest protein of the ULK1 complex by molecular weight,
has multiple reported functions. It was first characterized as a regulator of
retinoblastoma 1 (Rb1), hence its original name, Rb1-inducible Coiled-Coil 1
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(RB1CC1). Chano et al., the group that discovered this protein, found that
RB1CC1 localized to the nucleus and that expression levels of Rb1 in a variety of
cell types are positively correlated to RB1CC1 expression levels.13 This same
group later confirmed through ChIP-Seq and DNA foot-printing that RB1CC1
binds the Rb1 promoter to drive Rb1 expression.14 The Focal Adhesion Kinase
Interacting Protein of 200kD (FIP200) was discovered independently of the
discovery of RB1CC1, and in the context of autophagy instead of transcription
regulation.15
FIP200 is an obligate interactor of ULK1 in the induction of autophagy.
Hara et al. discovered that, in FIP200-/- MEF cells, LC3-II formation, a marker of
autophagic flux, is markedly decreased after starvation compared to WT MEF
cells.15 Additionally, Wei et al. were able to suppress autophagy by knocking out
FIP200 expression in mice, though they do not delineate whether this autophagy
is initiated by the ULK1 complex.16
The other two members of the ULK1 complex are ATG13 and ATG101.
ULK1 phosphorylation of FIP200 is mediated by ATG13, and LC3-II formation
is stalled in cells lacking either ATG13 or ATG101 expression. This suggests that
both ATG13 and ATG101 play an important, though unknown role in the
progression of autophagy. Recent studies by Kananngara and Poole et al. show
that ATG9A interacts with all four members of the ULK1 complex, but that
ATG9A also interacts with ATG13 and ATG101 when a ULK1 non-binding
mutant of ATG13 is introduced.17 These data suggest that ATG13 and ATG101
may interact with ATG9A in a ULK1-independent and ATG13-mediated manner,
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which suggests an ATG13-ATG101 complex that interacts with ATG9A. The role
of a putative ATG13-ATG101 complex remains unknown.
In the specific context of aggrephagy, the ULK1 complex has not been
implicated except in the context of metabolic stress.18 Otherwise, the induction
and regulation of aggrephagy is not well understood. Kananngara and Poole et al.
have shown that colocalization of ATG9A with p62 dramatically increases when
ATG13 expression is knocked out.17 This suggests some function of ATG13 in
the recruitment of autophagy machinery to the site of autophagophore formation,
which is not well characterized. This project aims to understand the molecular
mechanism of aggrephagy and is centered on characterizing the function of
ATG13 and ATG101 in ATG9A-mediated aggrephagy.
Here we demonstrate that ATG13 regulates ATG9A-mediated
aggrephagy in an ATG101-dependent manner. We also demonstrate that this
regulatory function is carried out independent of the ULK1 complex, suggesting
that aggrephagy may be stress signal-independent in some cases. Additionally, we
show that ATG13 is required for p62 degradation at a basal level. Lastly, we have
developed a novel protein fragment complementation (PFC) assay using the biotin
ligase TurboID to study the active ATG13-ATG101 complex directly and
distinguish its functions from those of ATG13 or ATG101 independently. Using
this assay, we have shown that ATG9A interacts with ATG13 and ATG101 in a
complete complex, independent of ULK1 and FIP200.
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METHODS

Cell Culture

Hct116 cells were split down to 20% confluency every 2-3 days with 0.05%
trypsin and Dulbecco’s Modified Eagle Medium (DMEM) supplemented with
10% (v/v) Fetal Bovine Serum and 1% (v/v) Penicillin/Streptomycin solution,
hereafter called complete DMEM.

Lentiviral Transduction

Lentivirus was generated with LentiX-293T cells. First, LentiX-293T cells were
seeded at 20% confluency, then transfected with the appropriate transgene, viral
packaging genes (psPAX2), and viral envelope genes (pMD2.G) in a 4:2:1 DNA
ratio. DNA was added to 300µL of serum-free DMEM while 56µg of the
transfection reagent PEI Max was added to an additional 300µL of serum-free
DMEM. These solutions were combined, vortexed, and allowed to incubate at
room temperature for 10 minutes. After incubation, the transfection solution was
diluted in 5mL of complete DMEM and added to cells for 8-12 hours in an
incubator at 37˚C and 5% CO2. After incubation, the transfection media was
replaced with 10mL of complete DMEM and allowed to incubate for an
additional 24 hours. Virus was collected at 24- and 48-hours post-transfection.
Virus was collected by filtering the cellular supernatant through a Steriflip
0.22µm vacuum filter. To produce cells stably expressing the Split TurboID
6

system, lentiviral transductions were performed on Hct116 cells in which ATG13
and ATG101 expression had been abolished and in which an HA tag had been
added to endogenous ATG9A via the CRISPR-Cas9 system. Hct116 HA KI
ATG13/ATG101 Double KO cells were infected for 8-16 hours with 4-5mL of
TurboID(C)-ATG13-Myc and TurboID(N)-ATG101-FLAG lentivirus solution
supplemented with polybrene to a final concentration of 10µg/mL. After
infection, cells were allowed to recover for 24 hours before selection. Cells were
selected with 3µg/mL of puromycin for at least 7 days before isolating
monoclonal populations. After transduction, monoclonal populations were
isolated via limited dilution methods.

Split TurboID Protein Fragment Complementation Assay

To perform the protein fragment complementation assay with TurboID, cells
expressing ATG13/ATG101 Split TurboID were incubated with 50µM biotin in
5mL of complete DMEM for 10 minutes at 37˚C and 5% CO2. Cells were then
harvested and lysed with ATG9 lysis buffer. Cell lysates were then used in
immunoblot and immunoprecipitation experiments.

Immunoblotting and Immunoprecipitation

To perform immunoprecipitation of biotinylated proteins, protein levels of cell
lysates in which proteins had been labeled with biotin were quantified using the
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Bio-Rad DC protein assay. These lysates were then incubated with streptavidinconjugated agarose beads at 4˚C with gentle rotation for 1-2 hours. Beads were
washed three times with ATG9A lysis buffer before being incubated for 5 minutes
at 95˚C in 1X SDS running buffer. After pelleting the beads, the supernatant,
containing biotinylated proteins, was loaded in a well of an SDS-PAGE gel. SDSPAGE was then performed at 150V for 1 hour.

After SDS-PAGE, proteins were transferred to a membrane using the iBlot Drytransfer system. The membrane was then blocked in a 5% (w/v) fat-free milk
solution in PBS-Tween for 1 hour. After blocking, the membrane was then
washed twice with PBS-T and once with PBS before being incubated overnight
with either the appropriate primary antibody or with a solution of fluorescently
labeled streptavidin at 4˚C with gentle rocking. The next day, the membrane was
again washed twice with PBS-T and once with PBS before incubating with
appropriate infrared fluorescent secondary antibody for 1 hour at room
temperature. If blotting with streptavidin, blots were immediately imaged after
overnight incubation. Finally, the membrane was washed once in PBS-T and
twice with PBS and then imaged using the Li-Cor Odyssey imaging system.
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RESULTS AND DISCUSSION

The loss of ATG13 or ATG101 results in an accumulation of p62 into
large condensates that colocalize with ATG9A
To determine the function of the ATG13 and ATG101 complex in
autophagic flux, we knocked out expression of ATG13, ATG101, ATG9A, and
FIP200 in Hct116 cells in which an HA affinity tag was knocked in via CRISPR
on the C-terminal end of ATG9A (hereafter called Hct116 HA KI cells). This
experiment was done with and without bafilomycin treatment. Bafilomycin is a
V-ATPase inhibitor that inhibits autophagic flux. Samples in which cells were
treated with bafilomycin represent a positive control for comparison of
deficiencies in autophagic flux. Autophagic flux was then evaluated by observing
levels of p62 by Western blot.
We observed that p62 builds up in untreated cells at levels similar to those
of the bafilomycin treated cells when ATG13 is knocked out. Additionally, when
ATG101 is knocked out of untreated cells, p62 also builds up significantly
compared to wild-type levels. This buildup of p62 is significantly reduced in
untreated cells in which either ATG9A or FIP200 are not expressed (Figure 1D).
Additionally, p62 levels are significantly higher in ATG13KO cells and ATG101
KO cells that have been treated with bafilomycin when compared to treated WT
cells. This suggests that ATG13 and ATG101 exacerbate the effects of
bafilomycin, indicating a possible role of these proteins in the regulation of latestage aggrephagy including docking of the autophagosome and eventual
degradation of cargo.
9

Imaging these cells by confocal microscopy, we observed that ATG9A
colocalizes with these accumulations of p62 in ATG13 KO and ATG101 KO
cells. In these images, p62 accumulates in distinct, large puncta in ATG13 and
ATG101 KO cells, while remaining diffuse an in comparatively small puncta in
WT cells. Additionally, ATG9A does not colocalize with p62 in FIP200KO cells
significantly more than in wild-type cells (Figure 1A-C). These data suggest that
ATG13 and ATG101 play a significant role in promoting autophagic flux,
whereas FIP200 has little observable effect.

FIGURE 1. The loss of ATG13 or ATG101 results in an accumulation of p62 into large
condensates that colocalize with ATG9A. (A) Confocal images of ATG9A colocalization with
p62 in indicated CRISPR KO cells. (B) Quantification of average surface area of p62 puncta.
(C) Quantification of ATG9A colocalization with p62. (D) Western blot showing endogenous
p62 levels in CRISPR KO clones treated with or without 100 nM Bafilomycin for 24 hrs. (E)
Quantification of p62 signal in D.
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ATG13-mediated rescue of ATG9A accumulation at p62 condensates
requires the ATG13 HORMA domain but is independent of ULK1
binding domain
To confirm that the observed colocalization of ATG9A with large p62
condensates is affected by ATG13 and ATG101 independent of ULK1, we
generated non-binding mutations of ATG13. We generated a ULK1 non-binding
mutant of ATG13 called ATG13 ∆2AA and an ATG101 non-binding mutant of
ATG13 called ATG13 ∆HORMA. ATG13 expression was abolished in Hct116
HA KI cells. These cells were then transduced with lentivirus containing either
WT ATG13, ATG13 ∆2AA, or ATG13 ∆HORMA transgenes. We then analyzed
these cells by confocal microscopy.
We observed a similar pattern in both ATG9A colocalization with p62
puncta and p62 puncta size. Depleting cells of ATG13 expression causes a
significant increase in colocalization between ATG9A and p62 puncta. The
addition of either wild-type ATG13 or ATG13 ∆2AA brings both ATG9A
colocalization with p62 puncta and p62 puncta size down to wild-type levels.
When ATG13 ∆HORMA is stably added back to ATG13 KO cells, ATG9A
colocalization with p62 and p62 puncta size return to levels similar to those of
ATG13 KO cells. With these data we show that ATG13-mediated promotion of
autophagic flux is independent of ULK1 and requires the interaction of ATG13
and ATG101 (Figure 2).
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FIGURE 2. ATG13-mediated rescue of ATG9A accumulation at p62 condensates
requires the ATG13 HORMA domain but is independent of the ULK1 binding
domain. (A) Confocal images of ATG9A colocalization with p62 in HCT-116
ATG9A-HA KI- ATG13 WT, ATG13 KO or ATG13 KO cells reconstituted with
ATG13 WT, ATG13 Δ2AA and ATG13 ΔHORMA. (B) Quantification of ATG9A
colocalization with p62 in A. (C) Quantification of p62 puncta surface area in A.

The loss of ATG13 causes impaired degradation of p62 and an
accumulation of ubiquitin at p62 condensates
To address the question of how ATG13 affects p62 stability, we
performed a pulse chase experiment using ATG9A-BirA-HA. In this experiment,
cells stably expressing ATG9A-BirA-HA either expressed (ATG13 WT) or did
not express (ATG13 KO) ATG13. These cells were pulsed with biotin for 12
hours, harvested at six-hour intervals, and analyzed by Western Blot. We
observed that p62 initially accumulates in ATG13 KO cells compared to ATG13
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WT cells. Following this initial accumulation, degradation of p62 is slowed
compared to ATG13 WT cells. These data show that ATG13 plays a role in
promoting the degradation of p62, consistent with previously shown data that
suggests a role of ATG13 in late-stage aggrephagy.
To ensure that these p62 accumulations are in fact condensates targeted by
aggrephagy, we analyzed ATG13 WT and ATG13 KO cells by confocal
microscopy. We found that p62 colocalizes significantly more with ubiquitin in
ATG13 KO cells compared to wild-type cells. This indicates that the lack of
ATG13 expression impairs p62 degradation and causes increased concentration of
ubiquitin at p62 condensates.

FIGURE 3. The loss of ATG13 causes an impaired degradation of p62 and an accumulation of
ubiquitin at p62 condensates. (A) HA-ATG9A-BirA was expressed in HCT-116 ATG13 WT
and KO cells. Cells were grown in full DMEM media, treated with 50 μM biotin for 12 hours,
washed in PBS, and incubated in full media for time indicated. Cells were then lysed and
incubated with streptavidin resin before immunoblotting with indicated antibodies. (B)
Quantification of biotinylated p62 in A. (C) Representative images of p62 colocalization with
ubiquitin. (D) Quantification of Ubiquitin/p62 colocalization.
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Split TurboID is a functional protein fragment complementation assay
which can be used to study the ATG13-ATG101 complex
While it is relatively straightforward to study the behavior of single
proteins through conventional means such as Western blot and confocal
microscopy, it is quite difficult to study the behavior and functions of a
heterodimer. One major limitation in our current data is the inability to
confidently assign function to the ATG13-ATG101 complex when we only study
the effects of manipulation to one or the other protein. It is known that ATG9A
interacts with ATG13 and ATG101 through ATG13; however, the interaction of
ATG9A with an ATG13-ATG101 complex is impossible to observe explicitly
using current methods. Additionally, it is impossible to distinguish the phenotype
of p62 accumulation or ATG9A colocalization with p62 condensates as being
regulated by ATG13 alone or in active complex with ATG101. Data gathered
from cells in which the ATG13 ∆HORMA mutant has been stably added back
only indicate that interaction between ATG13 and ATG101 is required at some
point for p62 accumulation and ATG9A-p62 colocalization to return to wild-type
levels. It is difficult for these data to distinguish an active ATG13-ATG101
complex from a transient, though obligate ATG13-ATG101 interaction.
To explicitly study the ATG13-ATG101 complex, we developed the split
TurboID protein fragment complementation assay for ATG13 and ATG101. This
assay, based on the split TurboID protein developed by the Dr. Alice Ting lab at
Sandford University takes advantage of the ability of TurboID, a biotin ligase, to
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regain functional tertiary structure after being recombinantly split in half.19 In this
assay, the C-terminal half of TurboID is cloned onto the N-terminus of ATG13Myc, while the N-terminal half of TurboID is cloned onto the N-terminus of
ATG101-FLAG. When these two constructs are co-expressed in cells, ATG13
and ATG101 are free to interact in their complex. Upon interaction, the two free
halves of TurboID come together and assume native tertiary structure and
TurboID regains its biotin ligase activity. Proteins that are in the proximity of the
ATG13-ATG101 complex are biotinylated and can be analyzed with a variety of
methods including Western blot and mass spectrometry. The great advantage of
this system is its specificity. Each half of TurboID on its own lacks biotin ligase
activity, meaning that proteins are only biotinylated when they interact with the
active ATG13-ATG101 complex. Additionally, the two halves of split TurboID
do not have enough affinity for each other to reconstitute on their own. They
require two interacting chaperones such as ATG13 and ATG101. Using this
assay, we can now distinguish between the active complex and transient
interaction (Figure 4A).
To validate this assay, we transiently co-expressed TurboID(C)-ATG13Myc with TurboID(N)-ATG101-FLAG as well as TurboID(C)-ATG13∆2AAMyc with TurboID(N)-ATG101-FLAG in HEK293 cells. Before harvesting, these
cells were spiked with 5 mL of 50µM biotin in complete DMEM and then
allowed to incubate for 10 minutes. These cells were then analyzed by Western
blot using a solution of fluorescently labeled streptavidin. We observed a streak of
biotinylated proteins across all molecular weights similar to that found in a full
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length TurboID control (Figure 4B). This is evidence that the split TurboID PFC
assay is functional.

The ATG13-ATG101 complex is directly observed to interact with
ATG9A
To observe the interaction of the independent ATG13-ATG101 complex, a
panel of TurboID(C)-ATG13 mutants were co-expressed with TurboID(N)ATG101-FLAG in Hct116 HA KI cells. We then performed a streptavidin
immunoprecipitation to isolate biotinylated proteins and analyzed these proteins
by Western blot.
ATG9A is biotinylated by the split TurboID ATG13-ATG101 system
independent of both ULK1 and FIP200. Additionally, ATG9A is not biotinylated
when an ATG9A non-binding mutant of ATG13 (ATG13 ∆ATG9A BD) is
expressed (Figure 4C). This suggests that the interaction between ATG9A and the
ATG13-ATG101 complex is completely independent of the canonical ULK1
complex and carried out through the ATG9 binding domain housed within the
HORMA domain of ATG13.
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FIGURE 4. Use of the split TurboID protein fragment complementation assay to
show that ATG9A interacts with the ATG13-ATG101 complex independent of
ULK1 and FIP200. (A) Split TurboID allows for the purification and subsequent
analysis of proteins biotinylated by the ATG13-ATG101 complex and not by
ATG13 or ATG101 alone. (B) Validation of the Split TurboID system via Western
Blot. HEK293T cells were transfected with either the Split TurboID system or
ATG9A-TurboID and treated with 50µM biotin for 10 minutes. (C) Split TurboID
system was expressed in Hct116 HA KI cells using indicated mutants of ATG13
(BD - binding domain). ATG9A interacts with the ATG13-ATG101 subcomplex
independent of ULK1 and/or FIP200 as indicated by biotinylation of ATG9A.
Binding between the ATG13-ATG101 complex and ATG9A requires the ATG9A
binding domain of ATG13.
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CONCLUSIONS AND FUTURE WORK
Our data support a model in which ATG13 and ATG101 act together in a
complex independent of the canonical ULK1 initiatory complex. We show that
this independent ATG13-ATG101 complex interacts with ATG9A (Figure 4C).
We also show that the absence of ATG13 expression causes a build-up of p62ubiquitin condensates that colocalize with ATG9A (Figure 3C-D). Lastly, we
show that ATG13 is required for optimal degradation of p62 (Figure 3A-B).
These data suggest a role of the ATG13-ATG101 complex in which the ATG13ATG101 complex interacts with ATG9A to promote ATG9A-mediated
aggrephagy.
The mechanism by which the ATG13-ATG101 complex regulates
aggrephagy remains uncharacterized and represents a fascinating avenue for
future investigation. We show that the ATG13-ATG101 complex has a role in
promoting the degradation of p62 (Figure 3A-B), implicating the complex in latestage aggrephagy. ATG13 and ATG101 are also necessary components in the
ULK1 initiatory complex, suggesting that the ATG13-ATG101 may have a role in
the initiation of aggrephagy. Further experimentation is required to fully elucidate
the mechanism of aggrephagy regulation by the ATG13-ATG101 complex.
Our data show that ATG9A colocalizes with p62 condensates independent
of ATG13 (Figure 1, Figure 2). In fact, ATG9A colocalization with p62 is
dramatically increased in the absence of ATG13. Additionally, we show that
ATG9A colocalizes with p62 independent of FIP200 (Figure 1A,C). This suggests
the possibility of a mechanism whereby ATG9A is recruited to p62-ubiquitin
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condensates independent of the canonical ULK1 complex. Already, AgudoCanlejo et al. show that the biophysical properties of p62 condensates support the
remodeling of lipid membranes, suggesting that p62 condensates themselves may
regulate aggrephagy induction and recruitment of ATG9A vesicles.20 The
characterization of this mechanism presents an additional avenue of future study.
Here we have characterized a function of ATG13 that is independent of
the ULK1 complex. Pervious data from Kananngara and Poole et al. along with
the data presented here suggest that the ATG13-ATG101 complex performs
functions independent of the canonical ULK1 complex, nearly all of which are
presently uncharacterized.17 Using the split TurboID system, we plan to use mass
spectrometry proteomics to study the protein interactome of the ATG13-ATG101
complex within and independent of the canonical ULK1 complex. This study will
direct future studies of the functions of the ATG13-ATG101 complex
independent of ULK1.
In conclusion, this study uncovers a mechanism in which the ATG13ATG101 complex regulates ATG9A-mediated aggrephagy independent of ULK1.
This complex acts to promote the degradation of p62-ubiquitin condensates.
Additionally, this study presents the discovery of an ATG13-ATG101 complex,
which interacts with ATG9A independent of both ULK1 and FIP200. Lastly, this
study describes the development of a protein fragment complementation assay
using the biotin ligase TurboID to further study the mechanism of aggrephagy
regulation by the ATG13-ATG101 complex. Taken together, the data presented
here provide a better understanding of the mechanism of aggrephagy regulation

19

and aid in the identification of therapeutic targets for diseases in which protein
aggregation is a primary etiology.
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